AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Dendritic cell vaccine to be used in trial for new cancer treatment.
2004 JAN 7 - (NewsRx.com & NewsRx.net) -- Aastrom Biosciences, Inc., (ASTM) announced the initiation of a phase I clinical trial in collaboration with investigators at Duke University Medical Center (Duke).
The clinical trial will evaluate a dendritic cell-based vaccine as a new treatment for an assortment of gastrointestinal (GI) system cancers, including colorectal, stomach and pancreatic cancers. The trial protocol proposes to examine the safety, feasibility, immune outcome and clinical efficacy of a vaccination that is produced by loading tumor-associated peptide antigens onto a patient's blood-derived dendritic cells produced using Aastrom's DCV-II dendritic cell vaccine production kit and the AastromReplicell System.
This trial is funded by a National Institutes of Health (NIH) grant awarded to Aastrom and is being conducted under a U.S. Food and Drug Administration (FDA) Investigational New Drug application that was submitted by Duke. The protocol for the trial is approved for accrual of up to 12 patients, and is expected to take up to 24 months to complete. In addition to determining safety and certain immune system and tumor endpoints, the trial will evaluate the number of vaccinations needed to elicit potent immunity against carcinoembryonic antigen (CEA), a tumor-specific protein. Aastrom's System is expected to produce sufficient, clinical amounts of patient-derived dendritic cells to allow each patient to receive multiple vaccinations.
"It is our strategy to initiate important collaborations, such as this one with Duke, to provide access to Aastrom's unique dendritic cell vaccine production and cells, which is intended to lead to new therapeutic products for the company. If a patient's immunity can be successfully induced, this approach to cancer vaccine treatment could offer tremendous benefits to a large number of cancer patients," said R. Douglas Armstrong, PhD, president, CEO and chairman of Aastrom.
"Furthermore, Aastrom's DCV-II product could provide a reliable vaccine ...
- Aastrom Biosciences Begins Site Testing New Dendritic Cell Vaccine Product for...
- Press release article from: PR Newswire March 15, 2001 700+ words
...beta site evaluation of Aastrom's DC-I dendritic cell product for use in vaccines...various forms of cancer. Aastrom's beta site testing...developing different types of dendritic cell vaccines. Aastrom believes that this combined...
- Aastrom Biosciences Announces CE Mark Approval For First Dendritic Cell Therapy...
- Press release article from: PR Newswire October 2, 2001 700+ words
...used to produce Aastrom's innovative proprietary dendritic cell product, the...antigens. The DC-I dendritic cell production product utilizes Aastrom's patented single...biologically robust, dendritic cell supply. Aastrom is meeting this...
- Aastrom Biosciences Completes Second CE Marked Dendritic Cell Therapy Product;...
- Press release article from: PR Newswire February 14, 2002 700+ words
...complete antigen-loaded dendritic cell vaccine, based on Aastrom's proprietary cultured dendritic cell, the Dendricell...companies active in dendritic cell vaccine research and...development. Zellera AG, Aastrom's German subsidiary...
- Aastrom Biosciences Receives NIH Grant for Dendritic Cell Vaccine Research; --...
- Press release article from: PR Newswire September 15, 2003 700+ words
...for an ovarian cancer dendritic cell vaccine, Aastrom is preparing to begin dendritic cell clinical studies in...completed patient-specific dendritic cell vaccine in human clinical trials. About Aastrom's Immunotherapy Program...
- Aastrom Biosciences Executes Evalaution Agreements With Leading German...
- Press release article from: PR Newswire April 19, 2001 700+ words
...therapeutic effect. Aastrom's DC-I dendritic cell product is intended...types of vaccines. Aastrom's DC-I dendritic cell product and the AastromReplicell...stronger, more effective dendritic cell therapies. Aastrom is pioneering the development...
- Aastrom Biosciences Gets CE Mark For Dendritic Cell Therapy Product.(Brief...
- Newspaper article from: Vaccine Weekly November 14, 2001 700+ words
...used to produce Aastrom's proprietary dendritic cell product, the Dendricell...antigens. The DC-I dendritic cell production product utilizes Aastrom's patented single...biologically robust, dendritic cell supply. Aastrom is meeting this...
- Aastrom's Dendritic Cell Vaccine Technology to Be Utilized in Duke University's...
- Press release article from: PR Newswire December 11, 2003 700+ words
...produced using Aastrom's DCV-II dendritic cell vaccine production...provide access to Aastrom's unique dendritic cell vaccine production...three disposable dendritic cell production kits...foundation for Aastrom's Cell Production...
- Aastrom Biosciences Completes CE Mark Requirements for Third Dendritic Cell...
- Press release article from: PR Newswire August 21, 2003 700+ words
...vaccines based on Aastrom's technology. "Dendritic cell-based cancer...antigen-loaded dendritic cell vaccines. Aastrom has installed...CPP business for dendritic cell production products...information, visit Aastrom's website at...